Healthcare upgrades, downgrades, and initiations for Tuesday

Galena Biopharma (GALE +6.8%initiated at Outperform at Oppenheimer. Price target is $6.

Veracyte (VCYT +7%) started at Outperform at Leerink (PT $17), William Blair, and Cowen (PT $16).

Surgical Care Affiliates (SCAI +2.8%) initiated at Buy at BofA. Price target is $34. Yesterday: Goldman starts SCAI at Neutral.

Heartware (HTWR +2.3%) started at Buy at CRT Capital. Price target is $109.

Mallinckrodt (MNK +2%initiated at Buy at Jefferies. Price target is $60.

Harvard Bioscience (HBIO +4.4%upgraded to Buy from Neutral at Sidoti.

Forest Labs (FRX +1.1%) upgraded to Neutral from Underweight at Piper. Price target hiked to $49 from $33.

Cardiovascular Systems (CSII +0.9%) cut to Hold at Benchmark. Price target is $35.

From other sites
Comments (1)
  • Budavar
    , contributor
    Comments (1411) | Send Message
    GALE is an intelligent speculation to triple or quadruple your investment in the bio-pharma field.
    Made my first stage investment back in September which tripled in value in less than 90 days.
    GALEN operates in a target market worth billions of dollars =
    my spec is that it will hit the jackpot in the next 24 months.
    Added to investment to-day.
    Tune in on GALE's presentation to a NY bio-pharma conclave come next Tuesday.
    26 Nov 2013, 01:04 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs